Nephroprotection: how to slow the progression of chronic renal insufficiency?

Most nephropathies are characterized by a progression that may result in end-stage renal failure (ESRF). Apart from the specific treatment implemented when possible, ESRF may be delayed by nephroprotective therapy. Following the definition of the risk factors likely to induce progressive renal disea...

Full description

Saved in:
Bibliographic Details
Published inNéphrologie & thérapeutique Vol. 1; no. 2; pp. 135 - 144
Main Authors Hannedouche, Thierry, Krummel, Thierry, Parvez-Braun, Laura
Format Journal Article
LanguageFrench
Published France 01.05.2005
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Most nephropathies are characterized by a progression that may result in end-stage renal failure (ESRF). Apart from the specific treatment implemented when possible, ESRF may be delayed by nephroprotective therapy. Following the definition of the risk factors likely to induce progressive renal disease, the various therapeutic strategies that may play a nephroprotective role are reviewed. The potential results are described with regard to published data, in particular randomised trials, as recommended by the evidence-based medicine principles. Blockade of the renin-angiotensin system plays a major role in terms of nephroprotection. However, this strategy should not replace lifestyle measures and pharmacological treatment of the metabolic disorders associated to nephropathies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ISSN:1769-7255